Mark G. Anderson

4.2k total citations · 1 hit paper
47 papers, 3.4k citations indexed

About

Mark G. Anderson is a scholar working on Molecular Biology, Oncology and Virology. According to data from OpenAlex, Mark G. Anderson has authored 47 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 18 papers in Oncology and 8 papers in Virology. Recurrent topics in Mark G. Anderson's work include HIV Research and Treatment (8 papers), HER2/EGFR in Cancer Research (6 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Mark G. Anderson is often cited by papers focused on HIV Research and Treatment (8 papers), HER2/EGFR in Cancer Research (6 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Mark G. Anderson collaborates with scholars based in United States, United Kingdom and India. Mark G. Anderson's co-authors include Stephen K. Tahir, Saul H. Rosenberg, Stephen W. Fesik, Christin Tse, Xiufen Yang, Lisa Roberts, Haichao Zhang, Alexander R. Shoemaker, Eric F. Johnson and Michael J. Mitten and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Mark G. Anderson

45 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

2008 1.5k citations Christin Tse, Alexander R. Shoemaker et al. Cancer Research profile →

Peers

Countries citing papers authored by Mark G. Anderson

Since Specialization

Citations

This map shows the geographic impact of Mark G. Anderson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark G. Anderson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark G. Anderson more than expected).

Fields of papers citing papers by Mark G. Anderson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark G. Anderson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark G. Anderson. The network helps show where Mark G. Anderson may publish in the future.

Co-authorship network of co-authors of Mark G. Anderson

This figure shows the co-authorship network connecting the top 25 collaborators of Mark G. Anderson. A scholar is included among the top collaborators of Mark G. Anderson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark G. Anderson. Mark G. Anderson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Hepatitis B Virus in People who Inject Drugs and Men who Have Sex With Men With HIV in India: A Cross-sectional Study 2024 ·Open Forum Infectious Diseases ·(unknown), (unknown), Hussain Syed Iqbal, Mark G. Anderson, Allison M. McFall, (unknown), Mary A. Rodgers, Aylur K. Srikrishnan, Ashwin Balagopal, Gregory M. Lucas, Shruti H. Mehta, David L. Thomas, Gavin Cloherty, Chloe L. Thio, Sunil S. Solomon	0
2	Sequence Notes: Near Full-Length Genome Analysis of the First-Reported HIV-1 Circulating Recombinant Form (CRF)_10CD in Uganda 2024 ·AIDS Research and Human Retroviruses ·Nicholas Bbosa, Vera Holzmayer, Deogratius Ssemwanga, Robert Downing, (unknown), Mark G. Anderson, Mary A. Rodgers, Pontiano Kaleebu, Gavin Cloherty	0
3	A Mixture Model for Estimating SARS-CoV-2 Seroprevalence in Chennai, India 2023 ·American Journal of Epidemiology ·Matt D. T. Hitchings, Eshan U. Patel, (unknown), Aylur K. Srikrishnan, Mark G. Anderson, (unknown), Amy Wesolowski, Hussain Syed Iqbal, Mary A. Rodgers, Shruti H. Mehta, Gavin Cloherty, Derek A. T. Cummings, Sunil S. Solomon	3
4	ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition 2021 ·BMC Cancer ·Mark G. Anderson, Qian Zhang, Luis E. Rodrı́guez, Claudie Hecquet, Cherrie K. Donawho, Peter Ansell, Edward B. Reilly	9
5	Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR 2021 ·Journal of Neuro-Oncology ·Kedar S. Vaidya, Michael J. Mitten, (unknown), Anatol Oleksijew, Cory Alvey, Hugh D. Falls, (unknown), Joann P. Palma, Peter Ansell, Andrew C. Phillips, Edward B. Reilly, Mark G. Anderson, Erwin R. Boghaert	9
6	Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate 2020 ·Molecular Cancer Therapeutics ·Mark G. Anderson, Hugh D. Falls, Michael J. Mitten, Anatol Oleksijew, Kedar S. Vaidya, Erwin R. Boghaert, Wenqing Gao, Joann P. Palma, Diana Cao, (unknown), Thomas John, Hui Gan, Andrew M. Scott, Edward B. Reilly	30
7	ABBV-399, a c-Met Antibody–Drug Conjugate that Targets Both MET –Amplified and c-Met–Overexpressing Tumors, Irrespective of MET Pathway Dependence 2016 ·Clinical Cancer Research ·Jieyi Wang, Mark G. Anderson, Anatol Oleksijew, Kedar S. Vaidya, Erwin R. Boghaert, Lora A. Tucker, Qian Zhang, Edward K. Han, Joann P. Palma, Louie Naumovski, Edward B. Reilly	104
8	Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell Lines 2010 ·Molecular Cancer Therapeutics ·Stephen K. Tahir, John Wass, Mary K. Joseph, Viswanath Devanarayan, Paul Hessler, Haichao Zhang, Steve W. Elmore, Paul E. Kroeger, Christin Tse, Saul H. Rosenberg, Mark G. Anderson	59
9	Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways 2009 ·Molecular Cancer Research ·Xuesong Liu, Edward K. Han, Mark G. Anderson, Yan Shi, Dimitri Semizarov, Gang Wang, Thomas McGonigal, Lisa Roberts, Loren Lasko, Joann P. Palma, Gui‐Dong Zhu, Thomas D. Penning, Saul H. Rosenberg, Vincent L. Giranda, Yan Luo, Joel Johansson, Eric F. Johnson, Alexander R. Shoemaker	77
10	ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor breakdown → 2008 ·Cancer Research ·Christin Tse, Alexander R. Shoemaker, Jessica Adickes, Mark G. Anderson, Jun Chen, Sha Jin, Eric F. Johnson, Kennan C. Marsh, Michael J. Mitten, Paul Nimmer, Lisa Roberts, Stephen K. Tahir, Xiao Yu, Xiufen Yang, Haichao Zhang, Stephen W. Fesik, Saul H. Rosenberg, Steven W. Elmore	1513
11	Inhibition of Aurora B kinase sensitizes a subset of human glioma cells to TRAIL concomitant with induction of TRAIL-R2 2008 ·Cell Death and Differentiation ·(unknown), Mark G. Anderson, Lora A. Tucker, Yu Shen, Keith B. Glaser, O. Jameel Shah	29
12	Influence of Bcl-2 Family Members on the Cellular Response of Small-Cell Lung Cancer Cell Lines to ABT-737 2007 ·Cancer Research ·Stephen K. Tahir, Xiufen Yang, Mark G. Anderson, Susan E. Morgan-Lappe, Aparna V. Sarthy, Jun Chen, Robert B. Warner, Shi‐Chung Ng, Stephen W. Fesik, Steve W. Elmore, Saul H. Rosenberg, Christin Tse	250
13	Integrative Genomic Analysis of Small-Cell Lung Carcinoma Reveals Correlates of Sensitivity to Bcl-2 Antagonists and Uncovers Novel Chromosomal Gains 2007 ·Molecular Cancer Research ·Edward T. Olejniczak, Charles Van Sant, Mark G. Anderson, Gang Greg Wang, Stephen K. Tahir, Guido Sauter, Rick Lesniewski, Dimitri Semizarov	53
14	Expression of VDR and CYP24A1 mRNA in human tumors 2005 ·Cancer Chemotherapy and Pharmacology ·Mark G. Anderson, Masaki Nakane, Xiaoan Ruan, Paul E. Kroeger, J. Ruth Wu-Wong	189
15	Differential Protein Analysis of Spasomolytic Polypeptide Expressing Metaplasia Using Laser Capture Microdissection and Two-dimensional Difference Gel Electrophoresis 2003 ·Applied immunohistochemistry & molecular morphology ·Jeffrey R. Lee, (unknown), H. Yamaguchi, Timothy C. Wang, James R. Goldenring, Mark G. Anderson	32
16	Sequence-Specific Binding of Poly(ADP-Ribose) Polymerase-1 to the Human T Cell Leukemia Virus Type-I Tax Responsive Element 2002 ·Virology ·Zhan Zhang, Ellen Hildebrandt, Cynthia M. Simbulan‐Rosenthal, Mark G. Anderson	34
17	Antigenic Variation of SIV: Mutations in V4 Alter the Neutralization Profile 1996 ·Virology ·(unknown), Mark G. Anderson, (unknown), Sanjay V. Joag, Opendra Narayan, M. Christine Zink, Janice E. Clements	47
18	Antigenic Variation of Molecularly Cloned SIVmac239 during Persistent Infection in a Rhesus Macaque 1993 ·Virology ·Sanjay V. Joag, Mark G. Anderson, Janice E. Clements, Michael F. McEntee, Dharam P. Sharma, Robert J. Adams, Opendra Narayan	23
19	Differences in Neutralization of Simian Lentivirus (SIV _MAC ) in Lymphocyte and Macrophage Cultures 1992 ·AIDS Research and Human Retroviruses ·Michael F. McEntee, Mark G. Anderson, M. D. Daniel, Robert J. Adams, Homayoon Farzadegan, Ronald C. Desrosiers, Opendra Narayan	7
20	Two strains of SIVmac show differential transactivation mediated by sequences in the promoter 1992 ·Virology ·Mark G. Anderson, Janice E. Clements	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact